564 related articles for article (PubMed ID: 18458123)
1. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
Aapro MS; Link H
Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
[TBL] [Abstract][Full Text] [Related]
2. Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications.
Gascón P
Oncologist; 2008; 13 Suppl 3():4-10. PubMed ID: 18458118
[TBL] [Abstract][Full Text] [Related]
3. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
4. European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment.
Repetto L; Moeremans K; Annemans L;
Cancer Treat Rev; 2006; 32 Suppl 2():S5-9. PubMed ID: 16725267
[TBL] [Abstract][Full Text] [Related]
5. Treatment options for anemia, taking risks into consideration: erythropoiesis-stimulating agents versus transfusions.
Spano JP; Khayat D
Oncologist; 2008; 13 Suppl 3():27-32. PubMed ID: 18458122
[TBL] [Abstract][Full Text] [Related]
6. Erythropoiesis-stimulating agents for anemic patients with cancer.
Sheikh S; Littlewood TJ
Expert Rev Hematol; 2010 Dec; 3(6):697-704. PubMed ID: 21091146
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolic events and erythropoiesis-stimulating agents: an update.
Dicato M
Oncologist; 2008; 13 Suppl 3():11-5. PubMed ID: 18458119
[TBL] [Abstract][Full Text] [Related]
8. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
9. Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.
Spaëth D
Expert Rev Anticancer Ther; 2008 Jun; 8(6):875-85. PubMed ID: 18533797
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study.
Ludwig H; Aapro M; Bokemeyer C; Macdonald K; Soubeyran P; Turner M; Albrecht T; Abraham I
Eur J Cancer; 2009 Jun; 45(9):1603-15. PubMed ID: 19278851
[TBL] [Abstract][Full Text] [Related]
11. Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma.
Katodritou E; Dimopoulos MA; Zervas K; Terpos E
Cancer Treat Rev; 2009 Dec; 35(8):738-43. PubMed ID: 19733008
[TBL] [Abstract][Full Text] [Related]
12. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
Aapro M; Spivak JL
Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
[TBL] [Abstract][Full Text] [Related]
13. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
Pirker R
Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
[TBL] [Abstract][Full Text] [Related]
14. Management of anemia in advanced breast and lung cancer patients in daily practice: results of a French survey.
Ray-Coquard I; Morère JF; Scotté F; Cals L; Antoine EC
Adv Ther; 2012 Feb; 29(2):124-33. PubMed ID: 22314432
[TBL] [Abstract][Full Text] [Related]
15. Editorial: anemia management with erythropoiesis-stimulating agents: a risk-benefit update.
Aapro MS
Oncologist; 2008; 13 Suppl 3():1-3. PubMed ID: 18458117
[No Abstract] [Full Text] [Related]
16. Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks.
Locatelli F; Gascón P
Oncologist; 2009; 14 Suppl 1():57-62. PubMed ID: 19762517
[TBL] [Abstract][Full Text] [Related]
17. The role of the pharmacist in optimizing the use of erythropoietin stimulating agents.
Gebara SN; Moubayed H
J Oncol Pharm Pract; 2010 Mar; 16(1):33-7. PubMed ID: 19401308
[TBL] [Abstract][Full Text] [Related]
18. Anemia management in oncology and hematology.
Spivak JL; Gascón P; Ludwig H
Oncologist; 2009; 14 Suppl 1():43-56. PubMed ID: 19762516
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietic stimulating agents.
Testa U
Expert Opin Emerg Drugs; 2010 Mar; 15(1):119-38. PubMed ID: 20158404
[TBL] [Abstract][Full Text] [Related]
20. Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions.
Hess G; Nordyke RJ; Hill J; Hulnick S
Am J Hematol; 2010 Nov; 85(11):838-43. PubMed ID: 20976794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]